Reminder: Invitation to Roche ’s virtual event at the 2022 ASCO Annual Meeting focusing on the oncology pipeline

  We are pleased to invite investors and analysts to participate in our virtual event onMonday,6 June2022, highlighting Roche data presented during the congress scientific program from June 3 – 7 2022 and our early-stage oncology portfolio.16:00 – 17:30 CEST / 15:00 - 16:30BST09:00 – 10:30 am CDT / 7:00 – 8:30 am PDT  The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CEST on the day of the event.>click here AgendaOncology late-stageportfolioupdateElenaBernedo-Arzac, SVP, Oncology Therapeutic Area Head Key Data at ASCO 2022- Glofitamab pivotal Ph1b data in 3L+DLBCL- Polivy Asian sub-population data from Ph3 POLARIX in 1L DLBCLGinnaLaporte, MD - VP,Global Head Lymphoma/CLL Clinical Development Oncology early R&D updateJohannaBendell, M.D., Head of Roche Pharma Research and Early Development (pRED) OncologyAndy Chan,M.D., Ph.D. Senior Vice President, Research Biology, Genentech Research& Early Development (gRED) Q&A  Access to virtual event (pre-registration required)Please pre-register for our webinarhere*.  Should you be unable to register for the webinar due to your company IT policy, please send an e-mail [e-mail].  A replay of the webcast will be available via>ir.roche.com *privacy notice  Best regards,  Bruno EschliHead of Investor Relations  Sabine Borngr äberInvestor Relations Officer  Roche Invest...

Source: Roche Investor Update - May 30, 2022 Category: Pharmaceuticals Source Type: news